Lipopolysaccharide enhances neurogenic plasma exudation in guinea-pig airways.
1. Lipopolysaccharide (LPS) is implicated in many pulmonary and airway inflammatory diseases. Tachykinins released from nerve endings increase vascular permeability. In this study, we have assessed the enhancement by LPS of tachykinin-mediated plasma exudation in guinea-pig airways, and examined the role of oxidants as well as leukocyte adherence. 2. LPS (100 microg kg(-1), i.v.) was administered 0-3 h before bilateral electrical stimulation of the cervical vagus nerves in animals anaesthetized with urethane and ventilated. Vagal stimulation increased vascular permeability in the airways. LPS enhanced the vagally-mediated plasma exudation with the peak effect at 1 h after LPS administration. LPS alone induced no significant plasma exudation. LPS also enhanced exogenous substance P (10(-8) mol kg(-1), i.v.)-induced plasma exudation. 3. The NK-1 receptor antagonist L-732,138 abolished vagally-induced plasma exudation and significantly inhibited the enhancement by LPS. Pretreatment with superoxide dismutase (SOD, 5000 U kg(-1), i.p.) did not affect the vagally-induced plasma exudation, but inhibited the LPS-enhanced neurogenic plasma leakage. The LPS-enhanced vagally-induced plasma exudation was not completely inhibited by either L-732,138 or SOD pretreatment alone, but was blocked by the combination of both pretreatments. 4. Neutrophil depletion by cyclophosphamide alone did not influence vagally-induced plasma exudation, but significantly inhibited the LPS-enhanced response. 5. In conclusion, we have demonstrated LPS enhanced neurogenic plasma exudation by augmenting the response to tachykinins, partly through NK-1 receptors, to directly increase vascular permeability or to enhance leukocyte adhesion-mediated endothelial cell injury. Tachykinins released from nerve endings may contribute to endotoxin-related airway inflammatory responses.
Kuo
H P
HP
Department of Thoracic Medicine II, Chang Gung Memorial Hospital, Taipei, Taiwan.
Hwang
K H
KH
Lin
H C
HC
Wang
C H
CH
Liu
C Y
CY
Lu
L C
LC
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005122:Exudates and Transudates / Q000187:drug effects / Q000378:metabolism; D006168:Guinea Pigs; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D009411:Nerve Endings / Q000378:metabolism*; D064729:Neurokinin-1 Receptor Antagonists; D009504:Neutrophils / Q000378:metabolism; D010275:Parasympathetic Nervous System / Q000502:physiology; D013047:Specific Pathogen-Free Organisms; D013482:Superoxide Dismutase / Q000494:pharmacology; D015320:Tachykinins / Q000378:metabolism / Q000494:pharmacology*; D014364:Tryptophan / Q000031:analogs & derivatives / Q000494:pharmacology
D008070:Lipopolysaccharides; D064729:Neurokinin-1 Receptor Antagonists; D015320:Tachykinins; C086089:3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan; D014364:Tryptophan; D013482:Superoxide Dismutase